|
|
Blood, Vol. 109, Issue 2, 546-551, January 15, 2007
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study
Blood Astermark et al.
109: 546
Supplemental materials for: Astermark et al, Vol 109, Issue 2, 546-551
The FENOC study group consists of the following investigators and centers:
T. Chernova, Kirov Regional Hemophilia Treatment Center, Kirov, Russian Federation
T. Andreeva, Russia Hemophilia Center, St Petersburg, Russian Federation
A. Batorova, National Hemophilia Center, Bratislava, Bratislava, Slovakia
R. Musso, Ospedale Ferrarotto, University of Catania, Catania, Italy
O. Plyushch, E. Lopatina, Russian Haemophilia Center of Russian Academy of Medical Science, Moscow, Russian Federation
A. Gringeri, A. Bianchi Bonomi Hemophilia and Thrombosis Centre, Milano, Italy
V. Vdovin, P. Svirin, Moscow Children’s Hematology Centre, Moscow, Russian Federation
B. Zulfikar, Istanbul University, Istanbul, Turkey
S. Zupančić Šalek, University Hospital Rebro, Zagreb, Croatia
N. Ewing, City of Hope National Medical Center, Duarte, CA
G. Tagariello, Haemophilia Centre Castelfranco Veneto Hospital, Castelfranco Veneto, Italy
H. M. van den Berg, Van Creveld Clinic, Utrecht, the Netherlands
S. Arkin, Long Island Jewish Comprehensive Hemophilia Center, New York, NY
F. Baghaei, Sahlgrenska University Hospital, Göthenburg, Sweden
J. Astermark, E. Berntorp, Malmö University Hospital, Malmö, Sweden
D. DiMichele, Weill Medical College of Cornell University, New York, NY
K. Kavakli, Ege University Hospital, Izmir, Turkey
R. Kulkarni, Michigan State University, East Lansing, MI
M. Morfini, Azienda Ospedaliero, Universitaria Careggi, Florence, Italy
S. Pipe, University of Michigan, Ann Arbor, MI
and Z. Vorlova, D. Habart, UHKT Haemophilia Center, Prague, Czech Republic
|
|
